Preview Mode Links will not work in preview mode

Oncology Overdrive

Oct 12, 2020

Pamela Kunz, MD, is an expert in GI cancers and a courageous voice against gender discrimination and harassment in health care. In this episode, Kunz shares her story and provides guidance for those facing these types of challenges.

  • Intro :04
  • About Kunz :13
  • The interview 1:45
  • How did you get where you are now? 2:04
  • Can you tell us about your recent transition from Stanford to Yale? 3:40
  • How did you decide to start speaking out? 6:54
  • How do you guide women who find themselves in a similar situation? 9:11
  • What happened after you came out with this information? 11:32
  • If you don’t witness it, you may not know it’s happening 14:27
  • What are some of the challenges you encountered after going public? 17:16
  • Don’t read the comments 18:45
  • Did you tell Yale this would come out before transitioning from Stanford? 20:43
  • The importance of having support 22:40
  • Moving the needle 24:56
  • At what point should people be reporting these things? 28:58
  • If no one’s reporting, things won’t change 43:07
  • The importance of mentors and sponsors 34:24
  • Do you think this experience has changed you as a leader? 36:21
  • Kunz’s take-home message 40:48
  • How to reach Dr. Kunz 42:00

Pamela Kunz, MD, is an associate professor of medicine in the Division of Oncology at Yale University School of Medicine; leader of the Gastrointestinal Cancers Program at Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center; and director of GI Medical Oncology within the Section of Medical Oncology.

We’d love to hear from you! Send your comments/questions to Dr. Jain at Dr. Kunz can be reached on Twitter at @PamelaKunzMD and via email at Follow us on Twitter @HemOncToday @ShikhaJainMD

Disclosures: Jain reports she is a paid freelance writer for Lippincott. Kunz reports stock and other ownership interests in Guardant Health; consulting or advisory roles with Advanced Accelerator Applications, Ipsen, Lexicon and Novartis; and research funding from Advanced Accelerator Applications, Brahms (Thermo Fisher Scientific), Ipsen, Lexicon and Xencor.